About this Journal Submit a Manuscript Table of Contents
ISRN Pharmacology
Volume 2012 (2012), Article ID 914168, 14 pages
http://dx.doi.org/10.5402/2012/914168
Review Article

Clinical Pharmacology in Sleep Medicine

Sleep Division, Neurology Department, Massachusetts General Hospital, Wang 720, Boston, MA 02114, USA

Received 30 April 2012; Accepted 7 June 2012

Academic Editors: T. Kumai, M. van den Buuse, and R. Villalobos-Molina

Copyright © 2012 Ashley Proctor and Matt T. Bianchi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Senthilvel, D. Auckley, and J. Dasarathy, “Evaluation of sleep disorders in the primary care setting: history taking compared to questionnaires,” Journal of Clinical Sleep Medicine, vol. 7, no. 1, pp. 41–48, 2011. View at Scopus
  2. J. Winkelman and R. Pies, “Current patterns and future directions in the treatment of insomnia,” Annals of Clinical Psychiatry, vol. 17, no. 1, pp. 31–40, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. K. Erman, “Therapeutic options in the treatment of insomnia,” Journal of Clinical Psychiatry, vol. 66, no. 9, pp. 18–23, 2005. View at Scopus
  4. T. J. Balkin, T. Rupp, D. Picchioni, and N. J. Wesensten, “Sleep loss and sleepiness: current issues,” Chest, vol. 134, no. 3, pp. 653–660, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. M. Ohayon, “From wakefulness to excessive sleepiness: what we know and still need to know,” Sleep Medicine Reviews, vol. 12, no. 2, pp. 129–141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. International Classification of Sleep Disorders, Diagnostic & Coding Manual, American Academy of Sleep Medicine, Westchester, Ill, USA, 2nd edition, 2005.
  7. A. D. Krystal, “The effect of insomnia definitions, terminology, and classifications on clinical practice,” Journal of the American Geriatrics Society, vol. 53, no. 7, pp. S258–S263, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. D. Edinger, M. H. Bonnet, R. R. Bootzin et al., “Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine work group,” Sleep, vol. 27, no. 8, pp. 1567–1596, 2004. View at Scopus
  9. D. E. Moul, E. A. Nofzinger, P. A. Pilkonis, P. R. Houck, J. M. Miewald, and D. J. Buysse, “Symptom reports in severe chronic insomnia,” Sleep, vol. 25, no. 5, pp. 553–563, 2002. View at Scopus
  10. M. M. Ohayon, “Epidemiology of insomnia: what we know and what we still need to learn,” Sleep Medicine Reviews, vol. 6, no. 2, pp. 97–111, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. W. V. McCall, “A psychiatric perspective on insomnia,” Journal of Clinical Psychiatry, vol. 62, no. 10, pp. 27–32, 2001. View at Scopus
  12. A. G. Harvey, “Insomnia: symptom or diagnosis?” Clinical Psychology Review, vol. 21, no. 7, pp. 1037–1059, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. M. J. Sateia, K. Doghramji, P. J. Hauri, and C. M. Morin, “Evaluation of chronic insomnia,” Sleep, vol. 23, no. 2, pp. 243–208, 2000. View at Scopus
  14. A. G. Harvey and N. K. Tang, “(Mis)perception of sleep in insomnia: a puzzle and a resolution,” Psychological Bulletin, vol. 138, no. 1, pp. 77–101, 2012.
  15. T. I. Morgenthaler, T. Lee-Chiong, C. Alessi et al., “Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders: an American Academy of Sleep Medicine report,” Sleep, vol. 30, no. 11, pp. 1445–1459, 2007. View at Scopus
  16. M. Zucconi and L. Ferini-Strambi, “Epidemiology and clinical findings of restless legs syndrome,” Sleep Medicine, vol. 5, no. 3, pp. 293–299, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Haba-Rubio, L. Staner, J. Krieger, and J. P. MacHer, “What is the clinical significance of periodic limb movements during sleep?” Neurophysiologie Clinique, vol. 34, no. 6, pp. 293–300, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. J. F. Gagnon, R. B. Postuma, S. Mazza, J. Doyon, and J. Montplaisir, “Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases,” Lancet Neurology, vol. 5, no. 5, pp. 424–432, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. http://www.uptodate.com/index.
  20. http://www.thompsonhc.com/micromedex2/.
  21. T. Barkoukis, J. K. Matheson, R. Ferber, and K. Doghramji, Therapy in Sleep Medicine, Elsevier, 2012.
  22. R. M. Benca, “Diagnosis and treatment of chronic insomnia: a review,” Psychiatric Services, vol. 56, no. 3, pp. 332–343, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. A. L. Meolie, C. Rosen, D. Kristo et al., “Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence,” Journal of Clinical Sleep Medicine, vol. 1, no. 2, pp. 173–187, 2005. View at Scopus
  24. L. Kierlin, “Sleeping without a pill: nonpharmacologic treatments for insomnia,” Journal of Psychiatric Practice, vol. 14, no. 6, pp. 403–407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Morgenthaler, M. Kramer, C. Alessi et al., “Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine Report,” Sleep, vol. 29, no. 11, pp. 1415–1419, 2006. View at Scopus
  26. J. D. Edinger and M. K. Means, “Cognitive-behavioral therapy for primary insomnia,” Clinical Psychology Review, vol. 25, no. 5, pp. 539–558, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. D. F. Kripke, “Chronic hypnotic use: deadly risks, doubtful benefit,” Sleep Medicine Reviews, vol. 4, no. 1, pp. 5–20, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Mohler, “GABA(A) receptor diversity and pharmacology,” Cell and Tissue Research, vol. 326, pp. 505–516, 2006.
  29. A. M. Holbrook, R. Crowther, A. Lotter, C. Cheng, and D. King, “Meta-analysis of benzodiazepine use in the treatment of insomnia,” Canadian Medical Association Journal, vol. 162, no. 2, pp. 225–233, 2000. View at Scopus
  30. S. R. Pandi-Perumal, J. C. Verster, L. Kayumov et al., “Sleep disorders, sleepiness and traffic safety: a public health menace,” Brazilian Journal of Medical and Biological Research, vol. 39, no. 7, pp. 863–871, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Tononi, “The neuro-biomolecular basis of alertness in sleep disorders,” Sleep Medicine, vol. 6, no. 1, pp. S8–S12, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Vassalli and D. J. Dijk, “Sleep function: current questions and new approaches,” European Journal of Neuroscience, vol. 29, no. 9, pp. 1830–1841, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. T. T. Dang-Vu, M. Desseilles, P. Peigneux, and P. Maquet, “A role for sleep in brain plasticity,” Pediatric Rehabilitation, vol. 9, no. 2, pp. 98–118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Dündar, S. Dodd, J. Strobl, A. Boland, R. Dickson, and T. Walley, “Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis,” Human Psychopharmacology, vol. 19, no. 5, pp. 305–322, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. D. J. Nutt and S. M. Stahl, “Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics,” Journal of Psychopharmacology, vol. 24, no. 11, pp. 1601–1612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. T. Bianchi, “The pharmacology of insomnia: targeting GABAA receptor function,” International Journal of Sleep Disorders, vol. 1, pp. 102–110, 2007.
  37. M. T. Bianchi and E. J. Botzolakis, “Targeting ligand-gated ion channels in neurology and psychiatry: is pharmacological promiscuity an obstacle or an opportunity?” BMC Pharmacology, vol. 10, article 3, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. M. T. Bianchi, “Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications,” Medical Hypotheses, vol. 74, no. 2, pp. 297–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. T. Bianchi, J. Pathmanathan, and S. S. Cash, “From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy,” Medical Hypotheses, vol. 72, no. 3, pp. 297–305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. T. Bianchi, “Non-serotonin anti-depressant actions: direct ion channel modulation by SSRIs and the concept of single agent poly-pharmacy,” Medical Hypotheses, vol. 70, no. 5, pp. 951–956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Rammes and R. Rupprecht, “Modulation of ligand-gated ion channels by antidepressants and antipsychotics,” Molecular Neurobiology, vol. 35, no. 2, pp. 160–174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. F. W. Turek and M. U. Gillette, “Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists,” Sleep Medicine, vol. 5, no. 6, pp. 523–532, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Buscemi, B. Vandermeer, N. Hooton et al., “The efficacy and safety of exogenous melatonin for primary sleep disorders: a meta-analysis,” Journal of General Internal Medicine, vol. 20, no. 12, pp. 1151–1158, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. C. B. Saper, G. Cano, and T. E. Scammell, “Homeostatic, circadian, and emotional regulation of sleep,” Journal of Comparative Neurology, vol. 493, no. 1, pp. 92–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. M. J. Thorpy, “Which clinical conditions are responsible for impaired alertness?” Sleep Medicine, vol. 6, supplement 1, pp. S13–S20, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Shahid, J. Shen, and C. M. Shapiro, “Measurements of sleepiness and fatigue,” Journal of Psychosomatic Research, vol. 69, no. 1, pp. 81–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. S. S. Sullivan and C. A. Kushida, “Multiple sleep latency test and maintenance of wakefulness test,” Chest, vol. 134, no. 4, pp. 854–861, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Shen, J. Barbera, and C. M. Shapiro, “Distinguishing sleepiness and fatigue: focus on definition and measurement,” Sleep Medicine Reviews, vol. 10, no. 1, pp. 63–76, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Curcio, M. Casagrande, and M. Bertini, “Sleepiness: evaluating and quantifying methods,” International Journal of Psychophysiology, vol. 41, no. 3, pp. 251–263, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. R. D. Chervin and M. S. Aldrich, “The multiple sleep latency test and Epworth sleepiness scale in the assessment of daytime sleepiness,” Journal of Sleep Research, vol. 9, no. 4, pp. 399–401, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. N. A. Eiseman, B. B. Westover, J. E. Mietus, R. J. Thomas, and M. T. Bianchi, “Classification algorithms for predicting sleepiness and sleep apnea severity,” Journal of Sleep Research, vol. 21, no. 1, pp. 101–112, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. D. J. Gottlieb, C. W. Whitney, W. H. Bonekat et al., “Relation of sleepiness to respiratory disturbance index: the sleep heart health study,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 2, pp. 502–507, 1999. View at Scopus
  53. R. D. Chervin, M. S. Aldrich, R. Pickett, and C. Guilleminault, “Comparison of the results of the Epworth Sleepiness Scale and the Multiple Sleep Latency Test,” Journal of Psychosomatic Research, vol. 42, no. 2, pp. 145–155, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. J. S. Ballon and D. Feifel, “A systematic review of modafinil: potential clinical uses and mechanisms of action,” Journal of Clinical Psychiatry, vol. 67, no. 4, pp. 554–566, 2006. View at Scopus
  55. M. H. Bonnet, T. J. Balkin, D. F. Dinges, T. Roehrs, N. L. Rogers, and N. J. Wesensten, “The use of stimulants to modify performance during sleep loss: a review by the Sleep Deprivation and Stimulant Task Force of the American Academy of Sleep Medicine,” Sleep, vol. 28, no. 9, pp. 1163–1187, 2005. View at Scopus
  56. B. Boutrel and G. F. Koob, “What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications,” Sleep, vol. 27, no. 6, pp. 1181–1194, 2004. View at Scopus
  57. A. Nehlig, “Are we dependent upon coffee and caffeine? A review on human and animal data,” Neuroscience and Biobehavioral Reviews, vol. 23, no. 4, pp. 563–576, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Childs, C. Hohoff, J. Deckert, K. Xu, J. Badner, and H. de Wit, “Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety,” Neuropsychopharmacology, vol. 33, no. 12, pp. 2791–2800, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. J. V. Rétey, M. Adam, E. Honegger et al., “A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15676–15681, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. B. B. Fredholm, K. Bättig, J. Holmén, A. Nehlig, and E. E. Zvartau, “Actions of caffeine in the brain with special reference to factors that contribute to its widespread use,” Pharmacological Reviews, vol. 51, no. 1, pp. 83–133, 1999. View at Scopus
  61. T. V. Dunwiddie and S. A. Masino, “The role and regulation of adenosine in the central nervous system,” Annual Review of Neuroscience, vol. 24, pp. 31–55, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. M. R. Littner, C. Kushida, W. M. Anderson et al., “Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder,” Sleep, vol. 27, no. 3, pp. 557–559, 2004. View at Scopus
  63. T. Lynch and A. Price, “The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects,” American Family Physician, vol. 76, no. 3, pp. 391–396, 2007. View at Scopus
  64. R. Sikka, B. Magauran, A. Ulrich, and M. Shannon, “Bench to Bedside: pharmacogenomics, adverse drug interactions, and the cytochrome P450 system,” Academic Emergency Medicine, vol. 12, no. 12, pp. 1227–1235, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. C. C. Ogu and J. L. Maxa, “Drug interactions due to cytochrome P450,” Proceedings (Baylor University. Medical Center), vol. 13, pp. 421–423, 2000.
  66. A. A. Izzo and E. Ernst, “Interactions between herbal medicines and prescribed drugs: an updated systematic review,” Drugs, vol. 69, no. 13, pp. 1777–1798, 2009. View at Publisher · View at Google Scholar · View at Scopus